TIGIT and central nervous system cancer: We found that the expression levels of CXCL2, CCL3, CCL4, CCL5, CCL8, CCL18, CXCL9, CXCL8, CXCL11, CXCL13, CD4, CCR5, CXCR3, CSF2, IGSF6, IL2RA, CD38, CD5, SDC1, GFI1, IL1R1, IL10, CCL20, IRF4, TRAF6, STAT5A, ICOS, SH2D1A, TIGIT, PDCD1 were higher in glioma tissues than in normal tissues (Figure 1D, p < 0.001); however, CXCL19, CXCL21, TNFRSF17, IL1R2, MS4A1, CD40, SGPP2, CD200, and FBLN7 were downregulated in glioma tissues (p < 0.001).